UBS: Gives MTR Corporation (00066) a "sell" rating with a target price of 21.6 Hong Kong dollars.
UBS said that due to the capital expenditure of the Sha Tin-Central Link being revised upwards from the previous guidance of HK$4.1 billion to HK$7 billion, the stock price of MTR Corporation (00066) is expected to have a slight negative reaction.
UBS released a research report stating that they give MTR CORPORATION (00066) a "sell" rating. They anticipate that the upcoming capital expenditures for the Hong Kong Northern Link project may face upward pressure due to inflation, with a target price of 21.6 Hong Kong dollars in the next 12 months.
The report states that MTR CORPORATION signed a project agreement with the Hong Kong government (represented by the Secretary for Transport and Housing) yesterday to determine the financing arrangements, design, construction, operation, and maintenance of the Hung Hom station. The estimated cost of the Hung Hom station is approximately 7 billion Hong Kong dollars at current prices.
The bank estimates that the reduction in the project unit price is still lower than the land premium paid by SHK PPT (00016) for the Fanling agricultural land in July. Considering that the capital expenditure for the Hung Hom station has been raised from the previous guidance of 4.1 billion Hong Kong dollars to 7 billion Hong Kong dollars, the stock price is expected to have a slightly negative reaction.
Related Articles

Revenue increased by 15% and profits surged by 27%, Western Alliance (WAL.US) Q3 financial report exceeded expectations and dispelled regional bank fears.

INNOVENT BIO (01801) and Takeda Pharmaceutical reached a global strategic cooperation agreement and issued shares under general authorization.

What is the recovery rate of creditors? Comparative analysis of Sunac, Greentown, and Jinke (00884).
Revenue increased by 15% and profits surged by 27%, Western Alliance (WAL.US) Q3 financial report exceeded expectations and dispelled regional bank fears.

INNOVENT BIO (01801) and Takeda Pharmaceutical reached a global strategic cooperation agreement and issued shares under general authorization.

What is the recovery rate of creditors? Comparative analysis of Sunac, Greentown, and Jinke (00884).

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025